AR107020A2 - Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) - Google Patents
Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)Info
- Publication number
- AR107020A2 AR107020A2 ARP160103766A ARP160103766A AR107020A2 AR 107020 A2 AR107020 A2 AR 107020A2 AR P160103766 A ARP160103766 A AR P160103766A AR P160103766 A ARP160103766 A AR P160103766A AR 107020 A2 AR107020 A2 AR 107020A2
- Authority
- AR
- Argentina
- Prior art keywords
- pcsk9
- kexina
- subtilisine
- type
- convertase protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
Abstract
Reivindicación 1: Un inmunógeno que comprende al menos un péptido antigénico de PCSK9 unido a un vehículo inmunogénico, donde el péptido antigénico PCSK9 consiste en la secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID Nº 46 - 101, 314, 318 y 319. Reivindicación 28: Una composición que comprende un inmunógeno de acuerdo con cualquiera de las reivindicaciones 1 a 3. Reivindicación 34: Una composición farmacéutica útil para el tratamiento del colesterol-LDL elevado o una condición asociada con el colesterol-LDL elevado, que comprende: (i) un inmunógeno de acuerdo con cualquiera de las reivindicaciones 1 a 3; y (ii) un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23954109P | 2009-09-03 | 2009-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107020A2 true AR107020A2 (es) | 2018-03-14 |
Family
ID=43413463
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103197A AR078247A1 (es) | 2009-09-03 | 2010-09-01 | Vacuna de pcsk9 |
ARP160103766A AR107020A2 (es) | 2009-09-03 | 2016-12-07 | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103197A AR078247A1 (es) | 2009-09-03 | 2010-09-01 | Vacuna de pcsk9 |
Country Status (30)
Country | Link |
---|---|
US (4) | US8889144B2 (es) |
EP (3) | EP2473605B1 (es) |
JP (5) | JP2013503623A (es) |
KR (3) | KR101512053B1 (es) |
CN (3) | CN104548089B (es) |
AR (2) | AR078247A1 (es) |
AU (1) | AU2010290931B2 (es) |
BR (1) | BR112012004807A2 (es) |
CA (2) | CA2846746A1 (es) |
CO (1) | CO6501190A2 (es) |
DK (1) | DK2473605T3 (es) |
ES (1) | ES2670576T3 (es) |
HK (3) | HK1174056A1 (es) |
HU (1) | HUE037416T2 (es) |
IL (2) | IL218229A (es) |
MX (1) | MX2012002639A (es) |
MY (1) | MY163512A (es) |
NO (1) | NO2473605T3 (es) |
NZ (3) | NZ710626A (es) |
PE (3) | PE20161551A1 (es) |
PH (2) | PH12016500004A1 (es) |
PL (1) | PL2473605T3 (es) |
PT (1) | PT2473605T (es) |
RU (2) | RU2538162C2 (es) |
SA (3) | SA114350179B1 (es) |
SG (3) | SG10201401516XA (es) |
SI (1) | SI2473605T1 (es) |
TR (1) | TR201808222T4 (es) |
TW (1) | TWI400085B (es) |
WO (1) | WO2011027257A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2328914T3 (en) | 2008-08-29 | 2017-07-10 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of P. gingivalis infection |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
CA2745096C (en) | 2008-12-09 | 2013-11-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
GB201005005D0 (en) * | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
US20140004142A1 (en) * | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
SI2570135T1 (sl) | 2011-09-13 | 2016-05-31 | Affiris Ag | PCSK9 cepivo |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
EP2908855B1 (en) * | 2012-10-17 | 2017-06-28 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae . |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US10117923B2 (en) | 2012-11-07 | 2018-11-06 | Vacplanta Limited | Production of an immunogen using a plant virus |
WO2014074509A1 (en) * | 2012-11-07 | 2014-05-15 | Vacplanta Limted | Production of an immunogen using a plant virus |
TWI641382B (zh) * | 2013-01-31 | 2018-11-21 | 韓美藥品股份有限公司 | 於包含因子vii之組成物中使病毒失活之方法 |
CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
KR102360250B1 (ko) * | 2014-02-28 | 2022-02-07 | 아피리스 아게 | Pcsk9 백신 |
CN104558199B (zh) * | 2014-09-05 | 2018-07-06 | 成都康弘生物科技有限公司 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
EP3258963A1 (en) * | 2015-02-18 | 2017-12-27 | Universität Zürich | Acetylated pcsk9 |
EP3325015B1 (en) * | 2015-07-20 | 2021-05-12 | Zoetis Services LLC | Liposomal adjuvant compositions |
CA3002323A1 (en) | 2015-10-19 | 2017-04-27 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
EP3370761A1 (en) * | 2015-11-03 | 2018-09-12 | Affiris AG | Method for vaccination against a self-antigen in a human patient |
KR102468907B1 (ko) * | 2016-03-25 | 2022-11-18 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 질환의 요인이 되는 생체내 단백질을 표적으로 하는 컨쥬게이트 백신 |
BR112018076242A2 (pt) * | 2016-06-24 | 2019-03-26 | Hoffmann La Roche | inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1 |
CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
MX2019012083A (es) * | 2017-04-13 | 2019-11-21 | Cadila Healthcare Ltd | Nueva vacuna de peptidos contra la pcsk9. |
CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
EP3826623A4 (en) | 2018-06-25 | 2022-03-23 | Duke University | COMPOSITIONS AND METHODS FOR TREATING CANCER CHARACTERIZED BY PCSK9 EXPRESSION |
US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
WO2021154947A1 (en) * | 2020-01-28 | 2021-08-05 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
AU2021229710A1 (en) | 2020-03-01 | 2022-10-06 | Dynavax Technologies Corporation | CPG-adjuvanted SARS-CoV-2 virus vaccine |
WO2022147373A1 (en) * | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
CN117327159A (zh) * | 2023-07-31 | 2024-01-02 | 杭州纽龙生物科技有限公司 | 一种蛋白a耐碱突变方法 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
WO1980000727A1 (en) | 1978-09-29 | 1980-04-17 | Secretary Energy Brit | Improvements in and relating to electrical power transmission in fluid wells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
AU548727B2 (en) | 1981-03-12 | 1986-01-02 | Gruppo Lepetit S.P.A. | Beta-lactam acetic acid derivatives |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
ATE75483T1 (de) | 1981-10-23 | 1992-05-15 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Dnaおよびその用途 |
IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
AU9052091A (en) | 1990-12-20 | 1992-07-22 | Smithkline Beecham Biologicals (Sa) | Vaccines based on hepatitis b surface antigen |
DE4202394A1 (de) | 1991-04-04 | 1992-10-08 | Teves Gmbh Alfred | Schwimmsattel-teilbelagscheibenbremse mit einem bremsengehaeuse aus leichtmetall |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
CN1185811A (zh) | 1995-03-31 | 1998-06-24 | H·沃尔夫 | 依赖于逆转录病毒样颗粒的抗原呈递系统 |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
DE69841122D1 (de) | 1997-03-10 | 2009-10-15 | Coley Pharm Gmbh | Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
AU755322B2 (en) | 1997-06-06 | 2002-12-12 | Dynavax Technologies Corporation | Inhibitors of DNA immunostimulatory sequence activity |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
PT1054689E (pt) | 1998-02-12 | 2003-11-28 | Immune Complex Corp | Proteinas no nucleo da hepatite e estrategicamente modificadas e seus derivados |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
US7745441B1 (en) | 1998-09-18 | 2010-06-29 | Wilex Ag | Urokinase inhibitors |
AU5728099A (en) | 1998-09-28 | 2000-05-01 | Hans Balle Aps | Lift, preferably for seats on wheelchairs |
US6203837B1 (en) | 1998-10-06 | 2001-03-20 | Xcafe' Llc | Coffee system |
WO2000023105A2 (en) | 1998-10-16 | 2000-04-27 | Smithkline Beecham Biologicals S.A. | Adjuvant systems and vaccines |
CA2347411C (en) | 1998-10-21 | 2012-04-03 | The Government Of The United States Of America | Virus-like particles for the induction of autoantibodies |
WO2000026385A1 (en) | 1998-11-05 | 2000-05-11 | Powderject Vaccines, Inc. | Nucleic acid constructs for genetic immunization |
JP2010510960A (ja) | 1998-11-30 | 2010-04-08 | サイトス バイオテクノロジー アーゲー | 抗原の順序付けられた分子提示、提示の方法、および使用 |
AU776828B2 (en) | 1998-12-21 | 2004-09-23 | Medimmune, Llc | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
BR9916477A (pt) | 1998-12-23 | 2004-06-22 | Shire Biochem Inc | Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
JP5084984B2 (ja) | 1999-02-17 | 2012-11-28 | シーエスエル、リミテッド | 免疫原複合体およびそれに関する方法 |
BR0009163A (pt) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
EP1204626B1 (en) | 1999-04-01 | 2008-01-16 | Esperion Therapeutics Inc. | Ether compounds, compositions, and uses thereof |
CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
CN1227030C (zh) | 1999-04-19 | 2005-11-16 | 史密丝克莱恩比彻姆生物有限公司 | 包含皂甙和免疫刺激寡核苷酸的佐剂组合物 |
NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
CA2383413A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
WO2001022990A2 (en) | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
EA200201077A1 (ru) | 2000-04-07 | 2003-04-24 | Юниверсити Оф Лидз Инновэйшнз Лимитед | Коровые антигенные химерные белки гепатита в |
EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
IL153558A0 (en) | 2000-06-20 | 2003-07-06 | Shire Biochem Inc | Streptococcus antigens |
ES2260235T3 (es) | 2000-06-22 | 2006-11-01 | Ucb Pharma Limited | Modificacion del antigeno "core" de la hepatitis b. |
WO2002005690A1 (en) | 2000-07-15 | 2002-01-24 | Lighthouse Display International Limited | Shelf edge display fittings |
GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
ES2335979T3 (es) * | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso. |
NZ531534A (en) | 2001-10-05 | 2005-10-28 | Cytos Biotechnology Ag | Angiotensin peptides conjugated with a carrier comprising a virus-like particle |
AU2002351623A1 (en) | 2001-12-20 | 2003-07-09 | Shire Biochem Inc. | Streptococcus antigens |
AU2003213168A1 (en) | 2002-02-21 | 2003-12-19 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
CN1668637B (zh) * | 2002-07-17 | 2010-05-26 | 希托斯生物技术股份公司 | 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列 |
GB0219524D0 (en) * | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
WO2004053091A2 (en) | 2002-12-10 | 2004-06-24 | Lorantis Ltd. | STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES |
RU2340627C2 (ru) | 2003-03-13 | 2008-12-10 | ГлаксоСмитКлайн Байолоджикалз с.а. | Способ очистки бактериального цитолизина |
EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
WO2006134423A2 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
EP1991678B2 (en) | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
CA2652247C (en) * | 2006-05-08 | 2015-11-17 | Adaerata, Limited Partnership | Chimeric pcsk9 proteins, cells comprising same, and assays using same |
US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
EP2142217B1 (en) * | 2007-03-27 | 2014-11-05 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted pcsk9 |
AR066042A1 (es) * | 2007-04-13 | 2009-07-22 | Novartis Ag | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) |
EP2687228B1 (en) | 2007-06-26 | 2017-07-19 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US8598320B2 (en) * | 2007-10-26 | 2013-12-03 | Merck Sharp & Dohme Corp. | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
CN101951943A (zh) | 2007-12-20 | 2011-01-19 | 赛托斯生物技术公司 | 神经生长因子偶联物及其用途 |
AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
AT507604A1 (de) | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
US10114918B2 (en) | 2016-01-27 | 2018-10-30 | Arm Limited | Physical placement control for an integrated circuit based on state bounds file |
ES2893464T3 (es) | 2016-06-23 | 2022-02-09 | Ripples Ltd | Procedimiento y aparato para imprimir en una bebida |
-
2010
- 2010-08-23 MX MX2012002639A patent/MX2012002639A/es active IP Right Grant
- 2010-08-23 BR BR112012004807A patent/BR112012004807A2/pt not_active Application Discontinuation
- 2010-08-23 DK DK10754583.2T patent/DK2473605T3/en active
- 2010-08-23 PL PL10754583T patent/PL2473605T3/pl unknown
- 2010-08-23 KR KR1020127005678A patent/KR101512053B1/ko not_active IP Right Cessation
- 2010-08-23 CN CN201510017173.9A patent/CN104548089B/zh not_active Expired - Fee Related
- 2010-08-23 PE PE2016002226A patent/PE20161551A1/es not_active Application Discontinuation
- 2010-08-23 NZ NZ710626A patent/NZ710626A/en not_active IP Right Cessation
- 2010-08-23 ES ES10754583.2T patent/ES2670576T3/es active Active
- 2010-08-23 KR KR1020137034292A patent/KR101660578B1/ko active IP Right Grant
- 2010-08-23 SG SG10201401516XA patent/SG10201401516XA/en unknown
- 2010-08-23 AU AU2010290931A patent/AU2010290931B2/en not_active Ceased
- 2010-08-23 SG SG10201401515YA patent/SG10201401515YA/en unknown
- 2010-08-23 CA CA2846746A patent/CA2846746A1/en not_active Abandoned
- 2010-08-23 NZ NZ620441A patent/NZ620441A/en not_active IP Right Cessation
- 2010-08-23 CN CN201080049440.6A patent/CN102612558B/zh not_active Expired - Fee Related
- 2010-08-23 KR KR1020137034291A patent/KR101660577B1/ko active IP Right Grant
- 2010-08-23 PE PE2016002242A patent/PE20161560A1/es not_active Application Discontinuation
- 2010-08-23 EP EP10754583.2A patent/EP2473605B1/en not_active Not-in-force
- 2010-08-23 CA CA2771770A patent/CA2771770A1/en not_active Abandoned
- 2010-08-23 JP JP2012527419A patent/JP2013503623A/ja not_active Withdrawn
- 2010-08-23 PE PE2012000286A patent/PE20121544A1/es active IP Right Grant
- 2010-08-23 PT PT107545832T patent/PT2473605T/pt unknown
- 2010-08-23 RU RU2012107657/10A patent/RU2538162C2/ru not_active IP Right Cessation
- 2010-08-23 TR TR2018/08222T patent/TR201808222T4/tr unknown
- 2010-08-23 EP EP18158216.4A patent/EP3358008A1/en not_active Withdrawn
- 2010-08-23 HU HUE10754583A patent/HUE037416T2/hu unknown
- 2010-08-23 CN CN201510017534.XA patent/CN104587462B/zh not_active Expired - Fee Related
- 2010-08-23 WO PCT/IB2010/053784 patent/WO2011027257A2/en active Application Filing
- 2010-08-23 NO NO10754583A patent/NO2473605T3/no unknown
- 2010-08-23 SG SG2012010740A patent/SG178447A1/en unknown
- 2010-08-23 NZ NZ599059A patent/NZ599059A/en not_active IP Right Cessation
- 2010-08-23 MY MYPI2012000934A patent/MY163512A/en unknown
- 2010-08-23 EP EP20140198381 patent/EP2865752A1/en not_active Withdrawn
- 2010-08-23 SI SI201031682T patent/SI2473605T1/en unknown
- 2010-08-27 TW TW099128951A patent/TWI400085B/zh not_active IP Right Cessation
- 2010-08-31 US US12/872,645 patent/US8889144B2/en not_active Expired - Fee Related
- 2010-09-01 SA SA114350179A patent/SA114350179B1/ar unknown
- 2010-09-01 SA SA114350178A patent/SA114350178B1/ar unknown
- 2010-09-01 SA SA110310687A patent/SA110310687B1/ar unknown
- 2010-09-01 AR ARP100103197A patent/AR078247A1/es not_active Application Discontinuation
-
2012
- 2012-02-20 IL IL218229A patent/IL218229A/en not_active IP Right Cessation
- 2012-02-24 CO CO12033031A patent/CO6501190A2/es unknown
-
2013
- 2013-01-23 HK HK13101001.0A patent/HK1174056A1/xx not_active IP Right Cessation
-
2014
- 2014-10-07 US US14/508,977 patent/US9481875B2/en not_active Expired - Fee Related
- 2014-10-29 RU RU2014143531A patent/RU2014143531A/ru not_active Application Discontinuation
-
2015
- 2015-02-04 JP JP2015020387A patent/JP5859150B2/ja not_active Expired - Fee Related
- 2015-09-11 HK HK15108893.4A patent/HK1208346A1/xx not_active IP Right Cessation
- 2015-10-21 HK HK15110331.0A patent/HK1209619A1/xx not_active IP Right Cessation
- 2015-12-15 JP JP2015244111A patent/JP2016106089A/ja not_active Withdrawn
-
2016
- 2016-01-04 PH PH12016500004A patent/PH12016500004A1/en unknown
- 2016-01-06 PH PH12016500040A patent/PH12016500040A1/en unknown
- 2016-09-15 US US15/266,812 patent/US9987341B2/en not_active Expired - Fee Related
- 2016-10-06 JP JP2016198088A patent/JP2017039748A/ja active Pending
- 2016-12-07 AR ARP160103766A patent/AR107020A2/es unknown
-
2017
- 2017-09-19 IL IL254600A patent/IL254600A0/en unknown
- 2017-10-06 JP JP2017195839A patent/JP2018039821A/ja active Pending
-
2018
- 2018-04-19 US US15/957,835 patent/US20180318407A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
CA2856891C (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen | |
SI2280721T1 (en) | IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS | |
PE20130314A1 (es) | PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
AR113257A1 (es) | Virus chikungunya inmunogénico | |
CL2019003407A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
JP2016502551A5 (es) | ||
WO2009152147A3 (en) | Compositions and methods for dengue virus (dv) treatment and vaccination | |
CY1113693T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων | |
CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
JP2012102105A5 (es) | ||
RU2013126888A (ru) | ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100 | |
AR083533A1 (es) | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe | |
AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
AR084095A1 (es) | Peptidos tomm34 y vacunas que los incluyen | |
AR065688A1 (es) | Conjugados de peptidos antifusogenicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |